Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Engraftment Syndrome Clear all
Terminated Phase 1Phase 2 Interventional

JSP191 Antibody Targeting Conditioning in SCID Patients

NCT02963064
View directory record Official record
Conditions
SCID
Interventions
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Biological
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
3 Months to 12 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

NCT01720264
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Hematopoetic Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
Interventions
Sitagliptin
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

NCT01471067
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Transplantation, Bone Marrow
Interventions
Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Cord Blood Infusion, Rituximab, ATG, Busulfan, Clofarabine, Total Body Irradiation (TBI)
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 10, 2026, 4:47 AM EDT
Terminated Phase 2 Interventional Results available

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

NCT00827099
View directory record Official record
Conditions
Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, fludarabine phosphate, Melphalan, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2012 · Synced Sep 10, 2026, 4:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

NCT03173937
View directory record Official record
Conditions
Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)
Interventions
Omidubicel (former CordIn), Miltenyi CliniMACS(R) CD34 Reagent System
Biological · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 10, 2026, 4:47 AM EDT
Recruiting Phase 3 Interventional

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

NCT05509933
View directory record Official record
Conditions
Engraftment Syndrome
Interventions
Budesonide
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 10, 2026, 4:47 AM EDT
No Longer Available No phase listed Expanded access

Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation

NCT02258490
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
G-CSF mobilized CD34+ selected cells for transplantation
Biological
Lead sponsor
Emory University
Other
Eligibility
17 Years to 75 Years
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment

NCT02099266
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS), Hodgkins Lymphoma, Non-Hodgkins Lymphoma
Interventions
Administration of hyperbaric oxygen
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
17 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 10, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

NCT07188090
View directory record Official record
Conditions
Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions
Plerixafor, Gcsf
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 10, 2026, 4:47 AM EDT
Completed No phase listed Observational

Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

NCT01622582
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant

NCT00092937
View directory record Official record
Conditions
Granulomatous Disease, Chronic
Interventions
Busulfan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Fecal Microbiota Transplantation Engraftment in IBS

NCT02847481
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
fecal microbiota transplantation, placebo fecal microbiota transplantation, FMT with antibiotic pre-treatment (v1), FMT with antibiotic pre-treatment (v2)
Procedure · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 10, 2026, 4:47 AM EDT
Active, not recruiting Phase 2 Interventional

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

NCT03739502
View directory record Official record
Conditions
AML, NHL, Hodgkin Disease, All, Myelodysplastic Syndrome
Interventions
Hyperbaric oxygen
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NCT00360685
View directory record Official record
Conditions
Mucositis, Graft-versus-host Disease
Interventions
Tac+MTX, TAC + MMF
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

NCT00923845
View directory record Official record
Conditions
Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome
Interventions
Pentostatin, Sirolimus, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplant (HSCT), Th2 rapa cells, Donor Lymphocyte Harvest, Induction Therapy, GVHD prophylaxis, Donor Hematopoietic Stem Cell Harvest
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 10, 2026, 4:47 AM EDT
Terminated No phase listed Observational

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

NCT00651716
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
flow cytometry, laboratory biomarker analysis, Data Collection
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 10, 2026, 4:47 AM EDT
Terminated Phase 1 Interventional

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

NCT01300611
View directory record Official record
Conditions
Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis, Acute Lymphoblastic Leukemia, Chronic Myelocytic Leukemia, Non Hodgkins Lymphoma, Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

NCT01471444
View directory record Official record
Conditions
Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
Interventions
Fludarabine, Clofarabine, Busulfan, Thymoglobulin, Stem Cell Infusion, Tacrolimus, Methotrexate
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease

NCT00001765
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Nexell Isolex with T-cell Depletion, Baxter isolex 300i
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer

NCT00005785
View directory record Official record
Conditions
Hematologic Neoplasm, HIV Infection
Interventions
GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 10, 2026, 4:47 AM EDT
Recruiting Not applicable Interventional

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

NCT01666080
View directory record Official record
Conditions
Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies
Interventions
Busulfan, Fludarabine, Total body irradiation, Stem cell transplant, Keppra
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 4:47 AM EDT
Terminated Early Phase 1 Interventional

Gene Therapy for Chronic Granulomatous Disease

NCT00394316
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 55 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 10, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Sitagliptin Umbilical Cord Blood Transplant Study

NCT00862719
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
Interventions
Sitagliptin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 10, 2026, 4:47 AM EDT